Capital Advisors Wealth Management LLC Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Advisors Wealth Management LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.4% during the first quarter, Holdings Channel reports. The institutional investor owned 3,162 shares of the biopharmaceutical company’s stock after acquiring an additional 298 shares during the quarter. Capital Advisors Wealth Management LLC’s holdings in Gilead Sciences were worth $354,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Annis Gardner Whiting Capital Advisors LLC grew its stake in shares of Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 216 shares during the period. Whipplewood Advisors LLC purchased a new stake in Gilead Sciences during the fourth quarter worth $35,000. Synergy Investment Management LLC acquired a new stake in Gilead Sciences during the fourth quarter valued at $40,000. Lee Danner & Bass Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at $41,000. Finally, Investment Research & Advisory Group Inc. raised its position in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares of the company’s stock, valued at $17,893,713.60. This represents a 1.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,500 shares of company stock worth $5,236,245 in the last three months. 0.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on GILD shares. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price on the stock. Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Stock Performance

GILD opened at $110.67 on Friday. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96. The firm has a market capitalization of $137.67 billion, a PE ratio of 23.30, a PEG ratio of 0.72 and a beta of 0.29. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The firm’s 50-day moving average price is $106.39 and its 200 day moving average price is $103.35.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business’s revenue was down .3% on a year-over-year basis. During the same period last year, the company posted ($1.32) EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date was Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.